Brokerages Expect Collegium Pharmaceutical, Inc. (NASDAQ:COLL) to Announce $0.93 Earnings Per Share

Wall Street brokerages expect Collegium Pharmaceutical, Inc. (NASDAQ:COLL) to announce earnings of $0.93 per share for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for Collegium Pharmaceutical’s earnings, with estimates ranging from $0.90 to $0.98. Collegium Pharmaceutical reported earnings per share of $0.32 during the same quarter last year, which would suggest a positive year-over-year growth rate of 190.6%. The business is scheduled to issue its next earnings report on Thursday, November 4th.

On average, analysts expect that Collegium Pharmaceutical will report full year earnings of $3.74 per share for the current year, with EPS estimates ranging from $3.65 to $3.87. For the next year, analysts anticipate that the company will report earnings of $4.21 per share, with EPS estimates ranging from $4.00 to $4.45. Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Collegium Pharmaceutical.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, August 5th. The specialty pharmaceutical company reported $0.27 EPS for the quarter, missing the Zacks’ consensus estimate of $0.34 by ($0.07). The business had revenue of $82.94 million during the quarter, compared to analyst estimates of $84.29 million. Collegium Pharmaceutical had a net margin of 32.73% and a return on equity of 22.59%.

A number of brokerages recently issued reports on COLL. HC Wainwright dropped their price objective on shares of Collegium Pharmaceutical from $33.00 to $28.00 and set a “buy” rating for the company in a report on Friday, August 6th. Zacks Investment Research raised shares of Collegium Pharmaceutical from a “strong sell” rating to a “strong-buy” rating and set a $23.00 price objective for the company in a report on Monday. Needham & Company LLC began coverage on shares of Collegium Pharmaceutical in a report on Friday, September 17th. They issued a “buy” rating and a $32.00 price objective for the company. Finally, Cantor Fitzgerald lowered shares of Collegium Pharmaceutical from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $30.00 to $22.00 in a report on Friday, August 6th.

Shares of NASDAQ COLL traded up $0.27 during mid-day trading on Wednesday, reaching $20.00. The company’s stock had a trading volume of 270,011 shares, compared to its average volume of 389,418. The stock has a 50-day moving average of $21.49 and a two-hundred day moving average of $22.72. The stock has a market capitalization of $711.28 million, a P/E ratio of 7.35, a P/E/G ratio of 0.71 and a beta of 0.89. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.32 and a current ratio of 1.40. Collegium Pharmaceutical has a 1-year low of $17.24 and a 1-year high of $26.91.

Hedge funds have recently made changes to their positions in the business. Captrust Financial Advisors purchased a new position in Collegium Pharmaceutical during the first quarter worth about $27,000. PNC Financial Services Group Inc. boosted its stake in Collegium Pharmaceutical by 245.9% during the second quarter. PNC Financial Services Group Inc. now owns 1,266 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 900 shares during the period. Royal Bank of Canada boosted its stake in shares of Collegium Pharmaceutical by 344.3% in the second quarter. Royal Bank of Canada now owns 3,110 shares of the specialty pharmaceutical company’s stock valued at $74,000 after purchasing an additional 2,410 shares during the period. Shell Asset Management Co. purchased a new position in shares of Collegium Pharmaceutical in the first quarter valued at approximately $99,000. Finally, Ensign Peak Advisors Inc purchased a new position in shares of Collegium Pharmaceutical in the first quarter valued at approximately $102,000.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc operates as a pharmaceutical company. The firm engages in the development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR.

Recommended Story: Understanding debt-to-equity ratio in fundamental analysis

Get a free copy of the Zacks research report on Collegium Pharmaceutical (COLL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.